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model selection, health states, hypotheses, survival analysis, clinical data sources 
and the treatment of uncertainty. Results: Twelve economic evaluations in oncol-
ogy were submitted to NICE by pharmaceuticals companies (PC) between 2013 and 
2015. Seven PC submitted a MCM, two a PSM, two a semi-markov partitioned sur-
vival model, and one a semi-markov model (SMM). Differences between modeling 
techniques were classified into four items: clinical data sources (e.g. published 
aggregated data for MCM and limited IPD for PSM), structure (e.g calculation of tran-
sition probabilities for MCM), hypotheses (e.g. same transition probability of death 
between two health states for MCM), flexibility of the model (e.g. access to patient 
level data for comparators required in PSM). ConClusions: Being a more flex-
ible modeling technique, Markov models remain more frequently used compared 
to PSM. Nevertheless, PSM represent a more straightforward option when patient 
level data are available but are inappropriate when such data are not accessible 
for comparators.
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objeCtives: To identify specific challenges for modelling to support health tech-
nology assessment (HTA) submissions using trial data where the comparator is the 
physician’s choice (PC). Methods: Most clinical trials are designed globally or inter-
nationally, with minimal consideration of individual market needs. It is increasingly 
common for investigational drugs to be compared against a mix of PC treatments 
because a standard of care (SOC) is not always clearly defined. We searched a clini-
cal trials database for registered trials where PC was the comparator. Based on the 
standard requirements for pharmacoeconomic models to support HTAs, we evaluated 
trial information to identify specific modelling challenges. Results: We found 49 reg-
istered trials using PC as the comparator and identified four specific challenges that 
require guidance from HTA bodies. (1) One or more drugs used in PC regimens may not 
be licensed for an individual market, rendering their use problematical. (2) Comparison 
made against individual PC drugs results in lower patient numbers for comparison, 
reducing analysis credibility. (3) Analysis against individual PC drugs requires breaking 
randomisation, which jeopardises trial design integrity. (4) Involvement of a PC mix 
results in the need for a full incremental analysis, which might lead to application 
rejections in circumstances where the new treatment may only have incremental 
benefits over some of the individual treatments. ConClusions: The use of PC as 
a comparator in clinical trials poses challenges that are likely to slow the process of 
access to effective, innovative treatments. HTA agency involvement early in the life 
cycle of a technology would facilitate a shared understanding of evidence require-
ments. HTA agencies should develop clear guidelines on how PC efficacy and cost 
should be used for pharmacoeconomic modelling.
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objeCtives: to evaluate the effect of the hydro-alcoholic leaves crude extract of 
Indigofera spicata(ISP) on the blood glucose level(BGL) of normoglycemic, oral glu-
cose loaded and alloxan induced diabetic rodents. Methods: The animals were 
randomly divided into five groups (n= 6) for all the aforementioned three models. In 
all models, group-I mice provided 2%tween-80, group-II were treated with 5mg/kg 
glibenclamide and the remaining three groups(III, IV &V) were treated with 100, 200, 
and 400mg/kg dose of the extract respectively. Statistical significance of differences 
in BGLs within and between groups was analyzed by SPSS version-21 using one 
way ANOVA followed by Tukey’s post hoc multiple comparison. Results: 200mg/
kg and 400mg/kg extract treated groups of normoglycemic mice showed significant 
(p< 0.05) BGL reduction compared to the pre-exposure level. In case of OGTT model 
BGL reduction was statistically significant (p< 0.05) in only 400mg/kg exposed groups 
at the 120 minute of post-exposure compared to the initial level. However, the BGL 
reducing effect of doses of the extract at the 4th, 6th and 10thhours of post treatment 
on diabetic mice was found statistically significant compared to both the negative 
control(p< 0.001) and their respective pretreatment levels(p< 0.05). ConClusions: 
Generally the crude extract of ISP leaves have shown prominent anti-diabetic effect 
and can be therefore used as a good insight for novel anti-diabetic drug discovery 
and development with a call of further in vitro and in vivo studies.
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objeCtives: To identify and assess disease progression models used in rheumatoid 
arthritis (RA) cost-effectiveness modelling. Methods: We examined all studies 
identified in two recent systematic literature reviews on health economic deci-
sion models evaluating RA treatments. We identified the elements in these studies 
describing disease progression and classified them by outcome measure affected 
and by model type. Results: Disease progression models concern in most cases 
the health assessment questionnaire (HAQ) score. The reported individual sampling 
models and discrete event simulation models make assumptions about improve-
ment of the HAQ when treated, depending on the patient’s type of response (e.g. 
remission, good, moderate or no response, measured by the American College of 
Rheumatology (ACR) response criteria or by the disease activity score 28 (DAS28)). 
Furthermore, they assume a long-term deterioration in the HAQ score and a rebound 
effect when the treatment stops, i.e. for example a complete loss of the initial 
Of 630 articles identified, four studies passed the inclusion criteria, and three were 
included by searching reference lists. Subsequently, we add more than 150 con-
ference papers to the screening three-step procedure. ConClusions: The use of 
modelling is promising in this context. It can be explained by the required features 
of any early cost-effectiveness evaluation seeking to inform decision making. We 
aimed at distinguishing from the previous works, addressing this methodology. It 
should be stressed the very small amount of the papers on the topic. In addition, 
we highlight the absence of ad-hoc checklist and coding to be used for the quality 
assessment of early model-based analyses and data extracted classification. This 
work also tries to advance in the definition of appropriate criteria to evaluate the 
reliability of the analysis in terms of impact on primary stakeholders.
PRM121
assessMent of validation of health-econoMics decision Models in 
inteRvention studies of seasonal influenza and bReast canceR
de Boer PT1, Frederix GW2, Al MJ3, Feenstra TF4, Vemer P1
1University of Groningen, Groningen, The Netherlands, 2Utrecht University, Utrecht, The 
Netherlands, 3Erasmus University, Rotterdam, The Netherlands, 4University Medical Center 
Groningen, Groningen, The Netherlands
objeCtives: We aimed to review recently published health-economic (HE) decision 
models to assess the reporting of validation efforts. An infectious disease (seasonal 
influenza, SI) and a chronic disease (breast cancer, BC) were used as examples, 
giving a preliminary insight in the reporting of validation efforts in the overall HE 
literature. Methods: A literature search was performed in Pubmed and Embase 
to retrieve full-text HE modeling studies, published between 2008 and 2014. Type 
of evaluation, model and intervention were extracted, as well as information on 
model outcomes, journal and funding. Reporting on model validation was evalu-
ated by checking for the presence of the word validation and its conjugates, and 
by using AdViSHE, a tool which contains a structured list of relevant items for vali-
dation. Results: The literature search resulted in 53 SI and 45 BC studies. In 41 
studies (42%) the word validation or its conjugates was mentioned, but only in a 
small percentage in the context of model validation. The terminology used around 
validation was found to be ambiguous. Model validation efforts were reported in 
a minority of studies. However, some studies do show good reporting examples. 
Cross validation of study outcomes was reported most often, but the quantity and 
quality of this reporting varied. More validation efforts were reported in BC than 
in SI. ConClusions: Only a limited number of studies reported on model valida-
tion efforts, although it may be assumed that more efforts have been taken than 
were reported. In particular, the differences between SI and BC may not mean that 
less efforts were undertaken to validate SI models. Although validation is deemed 
important by many researchers, this is not reflected in the reporting habits of HE 
modeling studies. Better reporting of validation efforts would be desirable to further 
enhance decision-makers’ confidence in HE models and their outcomes.
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objeCtives: As part of economic evaluations submitted to NICE, probabilistic and 
deterministic sensitivity analysis are a requirement, with probabilistic sensitivity 
analysis being a stated preference in the NICE reference case. The aim of including 
sensitivity analysis is to identify the key areas of uncertainty, and determine the 
impact on results. The aim of this analysis was to assess what impact uncertainty 
in cost-effectiveness models has had on NICE reimbursement decisions and review 
what type of sensitivity analyses are conducted. Methods: The five most recent 
NICE appraisals for breast cancer were selected, the sensitivity analysis results 
and methods were extracted. Once extracted the results of the sensitivity analysis 
were compared and contrasted. The sensitivity analysis results were considered 
in the context of the base case results. Results: The methodology of sensitivity 
analysis conducted varied between submissions, whilst all appraisals conducted 
univariate sensitivity analysis only two reported tornado diagrams. The method 
of reporting results also varied between appraisals, of the four appraisals that had 
more than one comparator in the base case, only one appraisal conducted a multi-
way cost-effectiveness acceptability analysis. ConClusions: There are many fac-
tors that impact a NICE committees decision, therefore it is not possible to draw a 
conclusion on how the uncertainty impacted the decision making process. Of the 
appraisals assessed, there was a wide range of differences between deterministic 
and probabilistic ICERs, however it appears that this did not impact the appraisal. 
The sensitivity analysis reported across NICE submissions lacks consistency in the 
observed sample, hindering the comparison between submissions.
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objeCtives: The choice of a modeling approach is guided by key criteria including 
time, interaction between individuals, and the unit of analysis (cohort or individuals 
level models). Despite Markov cohort modeling (MCM) is widely used in the litera-
ture, the use of partitioned survival (PS) models tends to increase. Our objective is 
to explore the rationale for selecting either a Markov modeling approach or a PS 
approach to carry-out a cost-effectiveness analysis in oncology. Our study focuses 
on the differences between the two approaches. Methods: A literature review 
focusing on survival modeling in economic evaluation was performed in order to 
establish a list of differences between the two modeling approaches. Besides, we 
reviewed NICE’s technology appraisals (TA) in oncology medicines over the last two 
years (2013-2015) to analyze the practices and the arguments put forward to justify 
modeling choices. Data collected for each TA included: model type, rationale for 
